Clinical Trials Logo

Clinical Trial Summary

This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with Radioactive Iodine-refractory Differentiated Thyroid Cancer (RAIR-DTC).

Clinical Trial Description

It is estimated that 10 patients who met the study criteria will be enrolled in 1 years and treated with Camrelizumab plus Apatinib in PUMCH. The investigators will follow up and collect subjects' data to evaluate the efficacy and safety of treatment, including objective response rate (ORR) and Progression-free Survival (PFS) and Overall Survival (OS), until disease progression or death. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04560127
Study type Interventional
Source Peking Union Medical College Hospital
Contact Yan-Song Lin
Phone 8601069155610
Status Recruiting
Phase Phase 2
Start date September 23, 2020
Completion date December 31, 2024